Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial publishing date : 2020 - 12 - 10 save search
UFP Industries announces agreement to acquire PalletOne, further expanding industrial packaging capabilities in the U.S.
Published: 2020-12-10 (Crawled : 21:06) - globenewswire.com
UFPI 4 | $113.89 1.16% 43K
|
Non-Energy Minerals
|
| O: 0.06%
H: 3.12%
C: 0.91%
trial
Passage Bio Receives MHRA Clinical Trial Authorization for PBGM01 for Treatment of GM1 Gangliosidosis
Published: 2020-12-10 (Crawled : 21:02) - globenewswire.com
PASG | News | $1.15 0.88% 11K
|
Health Technology
|
| O: -3.05%
H: 3.7%
C: 1.67%
trial treatment authorized
REGENXBIO Announces Dosing of First Patient in Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published: 2020-12-10 (Crawled : 18:00) - biospace.com/
RGNX | $16.15 3.26% 46K
|
Health Technology
|
| O: -0.28%
H: 4.02%
C: 0.08%
liver trial diabetic treatment diabetes
Fusion Pharmaceuticals Initiates Multi-Dose Portion of Phase 1 Trial of FPI-1434 in Patients with Advanced Solid Tumors
Published: 2020-12-10 (Crawled : 16:01) - biospace.com/
FUSN | $21.33 0.05% 260K
|
Health Technology
|
| O: 0.0%
H: 5.38%
C: 3.31%
trial phase 3 phase 1 phase 2 solid tumors
Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
HOTH | $1.15 9.6K
|
Health Technology
|
| O: 4.24%
H: 16.28%
C: 6.98%
dermatitis trial approval treatment atopic dermatitis phase 1b phase 2b
Hepion Pharmaceuticals Completes 75 mg CRV431 Dosing, Initiates 225 mg Dosing in Phase 2a 'AMBITION' Clinical Trial for NASH
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
HEPA | $1.39 -1.42% 27K
|
Health Technology
|
| O: -3.01%
H: 18.63%
C: 12.42%
trial nash phase 2b crv431
TG's New Drug Outshines Sanofi's Aubagio in MS Phase III Trial
Published: 2020-12-10 (Crawled : 16:00) - biospace.com/
SNY | News | $47.375 0.48% 300K
|
Health Technology
|
| O: -0.22%
H: 0.85%
C: 0.48%
drug trial new drug
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal TrialCompany Expects Interim Data in Mid-2021
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
TCON | $1.82 14K
|
Health Technology
|
| O: -2.98%
H: 10.13%
C: 7.28%
trial
Geron Announces Fifty Percent Enrollment Milestone in IMerge Phase 3 Clinical Trial in Lower Risk MDS
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
GERN | $3.71 -0.54% 2.1M
|
Health Technology
|
| O: 2.33%
H: 1.07%
C: -0.85%
risk phase 3 trial merge enroll milestone
INOVIO and Advaccine Announce First Dosing of Subject in Phase 2 Clinical Trial for COVID-19 DNA Vaccine Candidate INO-4800 in China
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
INO | $10.51 4.89% 99K
|
Health Technology
|
| O: -0.91%
H: 0.92%
C: 0.3%
covid china vaccine trial phase 2 ino-4800
Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Adolescents
Published: 2020-12-10 (Crawled : 15:00) - biospace.com/
MRNA | News S | $106.72 2.16% 510K
|
Health Technology
|
| O: -3.49%
H: 5.54%
C: 3.02%
covid vaccine phase 2 phase 2/3
First Patient Enrolled in Novocure’s Global Phase 3 TRIDENT Trial of Optune® Concurrent with Radiation Therapy in Newly Diagnosed Glioblastoma
Published: 2020-12-10 (Crawled : 14:00) - biospace.com/
NVCR | $12.24 3.47% 110K
|
Health Technology
|
| O: -0.71%
H: 7.13%
C: 5.19%
therapy radiation therapy phase 3 trial enroll glioblastoma
TRACON Pharmaceuticals Announces Dosing of First Patient in ENVASARC Pivotal Trial
Published: 2020-12-10 (Crawled : 13:06) - globenewswire.com
TCON | $1.82 14K
|
Health Technology
|
| O: -2.98%
H: 10.13%
C: 7.28%
trial
Bellicum Enrolls First Patient in Phase 1/2 Clinical Trial for BPX-603
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 4.43%
H: 6.71%
C: -1.41%
trial phase 3 phase 1 phase 2 enroll
BeyondSpring Announces New Positive PROTECTIVE-2 Phase 3 Registrational Trial Results at the 2020 San Antonio Breast Cancer Symposium
Published: 2020-12-10 (Crawled : 13:02) - globenewswire.com
BYSI | $2.11 14K
|
Health Technology
|
| O: 0.75%
H: 4.39%
C: 1.31%
breast cancer cancer positive results phase 3 trial trial results symposium
Spero Therapeutics Announces First Patient Dosed with SPR720 in Phase 2a Clinical Trial in Patients with Nontuberculous Mycobacterial Pulmonary Disease
Published: 2020-12-10 (Crawled : 13:01) - globenewswire.com
SPRO | $1.445 2.85% 46K
|
Health Technology
|
| O: -2.02%
H: 1.88%
C: 0.18%
disease trial phase 2b
Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET Trial at the 2020 SABCS
Published: 2020-12-10 (Crawled : 06:00) - biospace.com/
PBYI | $5.27 1.93% 59K
|
Health Technology
|
| O: 1.7%
H: 1.4%
C: -0.33%
biotech trial
Gainers vs Losers
| 89% | 11% |
Top 10 Gainers
MTTR | News M | $4.65 167.24% 9.8M
|
AGBA | $2.355 88.4% 34M
|
Finance
EDBL | News | $6.75 79.52% 1.5M
|
CZOO | $8.77 75.75% 11M
|
VNRX | $0.84 40.0% 2.6M
|
Health Technology
OPRT | News | $3.01 33.78% 6.8M
|
Finance
MLEC | $1.81 29.29% 2M
|
n/a
CMAX | $4.12 28.35% 65K
|
Manufacturing
MTC | $2.0 28.21% 1.7M
|
Technology Services
PEGY | $0.0586 27.95% 130M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.